These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3020591)

  • 21. Prostacyclin stimulation of the activation of blood coagulation factor X by platelets.
    Dutta-Roy AK; Ray TK; Sinha AK
    Science; 1986 Jan; 231(4736):385-8. PubMed ID: 3001935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistence of increased platelet cyclic AMP induced by prostaglandin E1 after removal of the hormone.
    Sinha AK; Colman RW
    Proc Natl Acad Sci U S A; 1980 May; 77(5):2946-50. PubMed ID: 6248875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostaglandin releasing polymers - stability and efficacy.
    McRea JC; Ebert CD; Kim SW
    Trans Am Soc Artif Intern Organs; 1981; 27():511-6. PubMed ID: 7036503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Conversion of prostacyclin to 6 oxo prostaglandin E1 by rat, rabbit, guinea-pig and human platelets.
    Griffiths RJ; Moore PK
    Br J Pharmacol; 1983 Oct; 80(2):395-402. PubMed ID: 6360281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stimulation of prostaglandin D2 receptors on human platelets by analogs of prostacyclin.
    Alvarez R; Eglen RM; Chang LF; Bruno JJ; Artis DR; Kluge AF; Whiting RL
    Prostaglandins; 1991 Aug; 42(2):105-19. PubMed ID: 1775633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Desacetyl-1-nantradol: a selective prostaglandin antagonist.
    Horne WC
    Prostaglandins Leukot Med; 1984 Jul; 15(1):129-36. PubMed ID: 6147860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diminished platelet adenylate cyclase activation by prostaglandin D2 in acute thrombosis.
    Cooper B
    Blood; 1979 Sep; 54(3):684-93. PubMed ID: 380688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of human platelets and polymorphonuclear neutrophils by the potent and metabolically stable prostaglandin D2 analog ZK 118.182.
    Darius H; Michael-Hepp J; Thierauch KH; Fisch A
    Eur J Pharmacol; 1994 Jun; 258(3):207-13. PubMed ID: 7522176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP.
    Haslam RJ; Davidson MM; Desjardins JV
    Biochem J; 1978 Oct; 176(1):83-95. PubMed ID: 215136
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concurrent down-regulation of IP prostanoid receptors and the alpha-subunit of the stimulatory guanine-nucleotide-binding protein (Gs) during prolonged exposure of neuroblastoma x glioma cells to prostanoid agonists. Quantification and functional implications.
    Adie EJ; Mullaney I; McKenzie FR; Milligan G
    Biochem J; 1992 Jul; 285 ( Pt 2)(Pt 2):529-36. PubMed ID: 1379045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
    Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Platelet sensitivity to antiaggregatory prostaglandins (PGE1,D2,I2) in patients with peripheral vascular disease.
    Fitscha P; Kaliman J; Sinzinger H
    Am J Hematol; 1985 May; 19(1):13-9. PubMed ID: 3885723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
    Fisch A; Michael-Hepp J; Meyer J; Darius H
    Eur J Pharmacol; 1995 May; 289(3):455-61. PubMed ID: 7556414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the multiplicity of platelet prostaglandin receptors. I. Evaluation of competitive antagonism by aggregometry.
    Andersen NH; Eggerman TL; Harker LA; Wilson CH; De B
    Prostaglandins; 1980 May; 19(5):711-35. PubMed ID: 6252573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 6-Keto-prostaglandin E1-sensitive adenylate cyclase and binding sites in membranes from platelets and cultured smooth muscle cells.
    Oliva D; Bernini F; Corsini A; Nicosia S
    Biochem Pharmacol; 1984 Dec; 33(23):3755-8. PubMed ID: 6391491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of heparin on prostacyclin binding and platelet adenylate cyclase activity stimulated by iloprost and forskolin.
    Jaschonek K; Faul C; Daiss W; Weisenberger H
    Prostaglandins Leukot Med; 1986 Oct; 24(2-3):199-206. PubMed ID: 2432618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of platelet cyclic nucleotide content by PGE1 and the prostaglandin endoperoxide PGG2.
    Miller OV; Gorman RR
    J Cyclic Nucleotide Res; 1976; 2(2):79-87. PubMed ID: 177467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Refractoriness of diabetic platelets to inhibitory prostaglandins.
    Lagarde M; Berciaud P; Burtin M; Dechavanne M
    Prostaglandins Med; 1981 Oct; 7(4):341-7. PubMed ID: 6273957
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stimulation of prostaglandin E1 binding to human blood platelet membrane by insulin and the activation of adenylate cyclase.
    Kahn NN; Sinha AK
    J Biol Chem; 1990 Mar; 265(9):4976-81. PubMed ID: 1969414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the platelet prostaglandin D2 receptor. Loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders.
    Cooper B; Ahern D
    J Clin Invest; 1979 Aug; 64(2):586-90. PubMed ID: 222813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.